Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Glenmark Of India, Forest Of U.S. Say COPD Drug Fails Phase II Trials

This article was originally published in PharmAsia News

Executive Summary

India's Glenmark Pharmaceuticals and U.S.-based Forest Laboratories said their drug to treat chronic obstructive pulmonary disease has failed to achieve goals in a Phase II clinical trial. The two drug makers were looking to the oglemilast drug for treating COPD as a potential blockbuster. It would have competed with Pfizer's Spiriva (tiotropium bromide), which, without competition, is expected to generate nearly $5 billion in annual sales by 2015. (Click here for more

Table

View full table

Tags:
Latest Headlines

Syngene Chief: Large Cap Biopharma Taking China 'Rotation' More Seriously

Annovis Faces A Race Against Time

Diversification Gains Momentum As Companies Look To Derisk China

Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma

See All
UsernamePublicRestriction

Register

SC072518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By